Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Phase 1TerminatedNCT03125200

ADC Therapeutics S.A.21 enrolled

Overview

This study evaluated ADCT-502 in participants with Advanced Solid Tumors with HER2 Expression. Participants participated in a dose-escalation phase (Part 1) and were due to participate in the dose expansion phase (Part 2). In Part 2, patients were due to receive the dose level identified in Part 1, but the study was terminated prior to the beginning of Part 2.

Study ADCT-502-101 was the first clinical study with ADCT-502 in participants with Advanced Solid Tumors with HER2 Expression. ADCT-502 is an antibody drug conjugate (ADC) composed of an engineered version of the humanized monoclonal antibody trastuzumab, directed against the human HER2 receptor, conjugated to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. ADCT-502 specifically binds to HER2, and once internalized, releases the PBD dimer to allow cross-linking of DNA and eventually trigger cell death. The study had 2 parts. In Part 1 (dose escalation) participants received an infusion of ADCT-502, at escalating doses. Part 1 continued until the maximum tolerated dose or the recommended dose(s) and schedule(s) for expansion were determined. In Part 2 (expansion), participants were due to be assigned to the recommended dose level of ADCT-502 identified in Part 1 by the Dose Escalation Steering Committee, but the study was terminated prior to the beginning of Part 2. For each participant, the study included a screening period (up to 28 days), a treatment period, and a follow-up period to assess disease progression and survival for up to 12 weeks after the last dose of study drug. The total study duration was dependent on overall participant tolerability to the study drug and response to treatment as participants were able to continue treatment until disease progression or unacceptable toxicity.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Interventions

ADCT-502DRUG

Intravenous Infusion

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Main Inclusion Criteria: * Male or female age 18 years or older * Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for their condition. * Eastern Cooperative Oncology Group (ECOG) performance status: Part 1: 0-2, Part 2: 0-1 * Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block or unstained slides to demonstrate HER2 expression. * Pathologic diagnosis of solid tumor malignancy that is locally advanced or metastatic at time of Screening with documented HER2 expression. * Part 2/Dose Expansion Only: Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * Absolute neutrophil count (ANC) ≥ 1500/mm3 (≥1.5× 109/L). * Platelet count ≥100,000 //mm3 (≥100 × 109/L). * Hemoglobin ≥ 9 g/L (≥5.6 mmol/L). * Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN); or ≤ 5.0 × ULN if liver metastases are present. * Total bilirubin ≤ 1.5× ULN (or ≤ 3× ULN, with direct bilirubin ≤1.5 × ULN, in participants with known Gilbert syndrome). * Creatinine ≤ 1.5× ULN; or, if serum creatinine \> 1.5 × ULN, a measured creatinine clearance must be \>60mL/min/1.73m2 as calculated by the Cockcroft and Gault equation for participants to be eligible. * Women of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least 16 weeks after the last dose of ADCT-502. Men with female partners who are of childbearing potential must agree that they or their partners will use a highly effective method of contraception from the time of giving informed consent until at least 16 weeks after the participant receives his last dose of ADCT-502. Main Exclusion Criteria: * Known history of ≥ Grade 3 hypersensitivity to a therapeutic antibody. * Known history of positive serum human anti-drug antibody (ADA) to trastuzumab. * Major surgical procedure or significant traumatic injury, radiotherapy, chemotherapy, targeted therapy, hormone therapy, or other anticancer therapy. * Failure to recover to Grade 0 or Grade 1 from acute non-hematologic toxicity due to previous therapy, prior to screening (with the exception of alopecia). * Central Nervous System (CNS) disease only. * Symptomatic CNS metastases or evidence of leptomeningeal disease. * Active cardiovascular disease or significant history thereof. * Other active disease including but not limited to ulceration of the upper gastrointestinal tract, autoimmune disease, HIV infection, active Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. * Breastfeeding or pregnant. * Other concurrent severe and/or uncontrolled medical conditions.

Locations (5)

Stanford Cancer Center

Palo Alto, California, United States

Roswell Park Cancer Institute

Buffalo, New York, United States

Memorial Sloan Kettering Memorial Hospital

New York, New York, United States

South Texas Accelerated Research Therapeutics, LLC

San Antonio, Texas, United States

Medical Oncology Clinic - Institut Jules Bordet

Brussels, Belgium

Outcomes

Primary Outcomes

Number of Participants Who Experienced Dose-Limiting Toxicities

Time frame: Day 1 to 3 Weeks (one cycle)

Number of Participants Who Experienced a Dose-Limiting Toxicity With a CTCAE Grade of 3 or Above

The Common Terminology Criteria For Adverse Events (CTCAE) Version 4 will be used.

Time frame: Day 1 to 3 Weeks (one cycle)

Number of Participants Who Experience At Least One Treatment Emergent Adverse Event (TEAE)

An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.